<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;A01A&quot;,&quot;href&quot;:&quot;atc/A01A.md&quot;},{&quot;label&quot;:&quot;triamcinolone&quot;}]"></div>

# triamcinolone

- **generic name:** triamcinolone
- **ATC codes:** `A01AC01`, `C05AA12`, `D07AB09`, `D07BB03`, `D07CB01`, `D07XB02`, `H02AB08`, `R01AD11`, `R03BA06`, `S01BA05`, `S02CA04`
- **DrugBank:** [DB00620](https://go.drugbank.com/drugs/DB00620) · **PubChem:** [CID 31307](https://pubchem.ncbi.nlm.nih.gov/compound/31307)
- **molar mass:** 394.4339 g/mol (C21H27FO6) — DrugBank
- **groups:** approved, investigational, vet_approved

## About

Triamcinolone is a glucocorticoid used to treat inflammation and related conditions such as dermatoses, keloids, joint problems, and macular edema. It is widely used in many forms, including skin, oral, nasal, inhaled, eye, and systemic preparations, and is also approved for veterinary use.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q1074056](https://www.wikidata.org/wiki/Q1074056) and the WHO ATC classification; not checked by a person.</small>

## Molecules and molar masses

> The molar mass each model uses to convert mass to molar concentration and to form a metabolite molecule for molecule. Looked up, never estimated: DrugBank for the drug, the paper's own value or the PubChem entry matched to the paper's name for a metabolite.

| molecule | role | molar mass (g/mol) | formula | source | PubChem | records |
|---|---|---|---|---|---|---|
| triamcinolone | parent | 394.434 | C21H27FO6 | DrugBank | [31307](https://pubchem.ncbi.nlm.nih.gov/compound/31307) | Beer_2003, French_2000, Oishi_2008 |
| triamcinolone acetonide | metabolite | 434.504 | C24H31FO6 | PubChem | [6436](https://pubchem.ncbi.nlm.nih.gov/compound/6436) | Beer_2003, French_2000, Oishi_2008 |

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-04 04:38 | 10:58 | 0/4/0 | 2/0/0 | 0/0/3 | 190,127/29,923 | ollama / qwen3.8:27b-mtp-q8_0 | 10 | 7/3 | 10/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.3). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: missing key parameters — none reported by this paper</sub><br><sub>route_to: `human_review`</sub> | [Beer_2003_reference](drugs/drug_triamcinolone/Triamcinolone_Beer2003_reference.md) | — | 1-compartment (no model) | 0 | Beer PM et al., Intraocular concentration and pharmacok…, Ophthalmology (2003) | [10.1016/S0161-6420(02)01969-3](https://doi.org/10.1016/S0161-6420(02)01969-3) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.25). The first reading is what the record holds.">cross-check: disputed</span> <span class="pk-badge pk-badge--species" title="Animal study (horse), not measured in people (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">horse</span><br><sub>blocking: C9 clearance/volume outside physiological window (implausible magnitude — unit/…</sub><br><sub>route_to: `human_review`</sub> | [French_2000_reference](drugs/drug_triamcinolone/Triamcinolone_French2000_reference.md) | — | 1-compartment (no model) | 4 | French K et al., Pharmacokinetics and metabolic effects…, Journal of veterinary pharm… (2000) | [10.1046/j.1365-2885.2000.00288.x](https://doi.org/10.1046/j.1365-2885.2000.00288.x) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.444). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: C9 clearance/volume outside physiological window (implausible magnitude — unit/…</sub><br><sub>route_to: `human_review`</sub> | [Kraus_2018_reference](drugs/drug_triamcinolone/Triamcinolone_Kraus2018_reference.md) | — | 1-compartment (no model) | 2 | Kraus VB et al., Synovial and systemic pharmacokinetics…, Osteoarthritis and cartilage (2018) | [10.1016/j.joca.2017.10.003](https://doi.org/10.1016/j.joca.2017.10.003) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.333). The first reading is what the record holds.">cross-check: disputed</span> <span class="pk-badge pk-badge--species" title="Animal study (rat), not measured in people (from the LLM relevance screen, p(non-human) 1.00).">rat</span><br><sub>blocking: C9 clearance/volume outside physiological window (implausible magnitude — unit/…</sub><br><sub>route_to: `human_review`</sub> | [Oishi_2008_reference](drugs/drug_triamcinolone/Triamcinolone_Oishi2008_reference.md) | — | 1-compartment (no model) | 3 | Oishi M et al., Pharmacokinetic behavior of intravitrea…, Japanese journal of ophthal… (2008) | [10.1007/s10384-008-0584-0](https://doi.org/10.1007/s10384-008-0584-0) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--species" title="In-vitro data (cells, tissue or microsomes), not measured in people (from the LLM relevance screen, p(non-human) 1.00).">in vitro</span> | [Katsu_2022_fold_activation](drugs/drug_triamcinolone/pd_Katsu_2022_fold_activation.md) | transcriptional activation of full-length lungfish MR ← triamcinolone · direct Emax (saturable) effect | — | Katsu Y et al., Aldosterone and dexamethasone activate…, The Journal of steroid bioc… (2022) | [10.1016/j.jsbmb.2021.106024](https://doi.org/10.1016/j.jsbmb.2021.106024) |
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--species" title="In-vitro data (cells, tissue or microsomes), not measured in people (from the LLM relevance screen, p(non-human) 1.00).">in vitro</span> | [Katsu_2022_fold_activation_2](drugs/drug_triamcinolone/pd_Katsu_2022_fold_activation_2.md) | transcriptional activation of truncated lungfish MR ← triamcinolone · direct Emax (saturable) effect | — | Katsu Y et al., Aldosterone and dexamethasone activate…, The Journal of steroid bioc… (2022) | [10.1016/j.jsbmb.2021.106024](https://doi.org/10.1016/j.jsbmb.2021.106024) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Rohatagi_1995_cortisol](drugs/drug_triamcinolone/pd_Rohatagi_1995_cortisol.md) | cortisol ← triamcinolone acetonide · direct linear effect | — | Rohatagi S et al., Pharmacokinetic and pharmacodynamic eva…, Journal of clinical pharmac… (1995) | [10.1002/j.1552-4604.1995.tb04045.x](https://doi.org/10.1002/j.1552-4604.1995.tb04045.x) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Rohatagi_1995_granulocytes](drugs/drug_triamcinolone/pd_Rohatagi_1995_granulocytes.md) | granulocytes ← triamcinolone acetonide · direct Emax (saturable) effect | — | Rohatagi S et al., Pharmacokinetic and pharmacodynamic eva…, Journal of clinical pharmac… (1995) | [10.1002/j.1552-4604.1995.tb04045.x](https://doi.org/10.1002/j.1552-4604.1995.tb04045.x) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Rohatagi_1995_lymphocytes](drugs/drug_triamcinolone/pd_Rohatagi_1995_lymphocytes.md) | lymphocytes ← triamcinolone acetonide · direct Emax (saturable) effect | — | Rohatagi S et al., Pharmacokinetic and pharmacodynamic eva…, Journal of clinical pharmac… (1995) | [10.1002/j.1552-4604.1995.tb04045.x](https://doi.org/10.1002/j.1552-4604.1995.tb04045.x) |

## Pharmacogenomics (PGx)

| status | gene | affects | mechanism | detail | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--green" title="re-read by gpt-oss:120b (confirmed, agreement 1.0). The first reading is what the record holds.">cross-checked ✓</span> | **HCG22** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [Jeong_2015](drugs/drug_triamcinolone/pgx_Jeong_2015_HCG22_Q100.md) | Jeong S et al., Identification of a Novel Mucin Gene HC…, Investigative ophthalmology… (2015) | [10.1167/iovs.14-14803](https://doi.org/10.1167/iovs.14-14803) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--green" title="re-read by gpt-oss:120b (confirmed, agreement 1.0). The first reading is what the record holds.">cross-checked ✓</span> | **NR3C1** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [Obeidat_2019](drugs/drug_triamcinolone/pgx_Obeidat_2019_NR3C1_Q100.md) | Obeidat M et al., The pharmacogenomics of inhaled cortico…, The European respiratory jo… (2019) | [10.1183/13993003.00521-2019](https://doi.org/10.1183/13993003.00521-2019) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--green" title="re-read by gpt-oss:120b (confirmed, agreement 1.0). The first reading is what the record holds.">cross-checked ✓</span> | **unknown** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | unknown | [Obeidat_2019](drugs/drug_triamcinolone/pgx_Obeidat_2019_unknown_Q100.md) | Obeidat M et al., The pharmacogenomics of inhaled cortico…, The European respiratory jo… (2019) | [10.1183/13993003.00521-2019](https://doi.org/10.1183/13993003.00521-2019) |

<details class="pk-legend"><summary>What the PGx badges mean — evidence, and whether a model runs</summary><table><tbody><tr><td><span class="pk-badge pk-badge--green">quantitative</span></td><td>the paper gives the effect of each phenotype (or genotype) on a named model parameter — a θ per category.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">qualitative</span></td><td>the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">guideline estimate</span></td><td>the effect comes from a CPIC / DPWG dosing guideline, not from this paper's numbers.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">safety allele</span></td><td>a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>the extraction is incomplete or inconsistent.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted.</td></tr><tr><td><span class="pk-badge pk-badge--green">▶ simulatable</span></td><td>the paper's popPK model runs per phenotype in the browser (Simulation tab); its PGx Modelica model is under Models.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">model only</span></td><td>a PGx Modelica model exists but has no in-browser simulator.</td></tr></tbody></table></details>

<details class="legend">
<summary>What the PGx columns mean</summary>
<table><thead><tr><th>column</th><th>what it holds</th></tr></thead><tbody><tr><td><code>gene</code></td><td>the gene whose variants the record is about. One record per gene, so a paper reporting several genes appears on several rows.</td></tr><tr><td><code>affects</code></td><td>the PK or PD parameter the genotype SHIFTS, as an ontology Q-code plus its name — Q22 = clearance, Q27 = CL/F (apparent clearance), Q32 = Cmax, Q88 = AUC, Q40 = Fab, Q321 = EC50, Q322 = IC50, Q305 = kfm. The record's per-phenotype theta is a multiplier ON that parameter: a poor-metaboliser theta shifts this value, it does not supply one. Two values are NOT parameters — Q100 (NIL) is an association or risk finding with no parameter target, and `safety` is an adverse-reaction risk such as an HLA allele. A PA… id instead of a Q-code marks a record derived from a ClinPGx/PharmGKB guideline lookup rather than read out of the paper.</td></tr><tr><td><code>mechanism</code></td><td>how the gene acts: metabolism, transport, target, formation, safety_allele, or unknown.</td></tr><tr><td><code>detail</code></td><td>the paper stem, linking to the full record page.</td></tr><tr><th colspan="2" style="text-align:left;padding-top:10px">placeholders</th></tr><tr><td><code>not captured</code></td><td>the field is absent from the KB artifact — nothing was recorded. This is NOT the same as zero or empty: the value is unknown, not measured to be nothing.</td></tr><tr><td><code>—</code></td><td>deliberately not shown: the column does not apply to this row.</td></tr><tr><td><code>not verified</code></td><td>the record is not in an accepted state (see the badge and the note above the table); the numbers are shown as extracted, not endorsed.</td></tr></tbody></table>
</details>

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=triamcinolone) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | lung | <sub>named in DrugBank's ADME text</sub> | prose |
| distribution | blood | `ALB` binder | DrugBank actor |
| metabolism | blood | `BCHE` inducer | DrugBank actor |
| metabolism | kidney | `CYP3A5` inducer/substrate | DrugBank actor |
| metabolism | liver | `BCHE` inducer, `CYP3A4` inducer/substrate, `CYP3A5` inducer/substrate, `CYP3A7` inducer/substrate | DrugBank actor |
| metabolism | small intestine | `CYP3A4` inducer/substrate, `CYP3A5` inducer/substrate | DrugBank actor |
| excretion | kidney | <sub>named in DrugBank's ADME text</sub> | prose |

<sub>Actors without a tissue in the table: HCG22 (target), NR3C1 (target), PTGS2 (inhibitor), SERPINA6 (binder), UNKNOWN (unknown).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 67 matched, 40 returned
- **screened:** 4  ·  **relevant:** 4
- **records:** 4  ·  extracted 0  ·  needs_review 0  ·  rejected 4  ·  stale 0
- **scholar-agent fallback query used:** not captured

## Full text wanted

_11 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Beer_2003.pdf` | Beer PM et al., Intraocular concentration and pharmacok…, Ophthalmology (2003) | popPK | 10 | [10.1016/S0161-6420(02)01969-3](https://doi.org/10.1016/S0161-6420(02)01969-3) | [12689886](https://pubmed.ncbi.nlm.nih.gov/12689886) | The study reports quantitative pharmacokinetic parameters (half-life, AUC, peak concentration) for triamcinolone acetonide in humans, with specific numeric values provided in the abstract. |
| `French_2000.pdf` | French K et al., Pharmacokinetics and metabolic effects…, Journal of veterinary pharm… (2000) | popPK | 9 | [10.1046/j.1365-2885.2000.00288.x](https://doi.org/10.1046/j.1365-2885.2000.00288.x) | [11107002](https://pubmed.ncbi.nlm.nih.gov/11107002) | The study reports quantitative PK parameters (half-lives, volume ratios) for triamcinolone acetonide in horses, though specific clearance and volume values are not explicitly listed in the text. |
| `Oishi_2008.pdf` | Oishi M et al., Pharmacokinetic behavior of intravitrea…, Japanese journal of ophthal… (2008) | popPK | 9 | [10.1007/s10384-008-0584-0](https://doi.org/10.1007/s10384-008-0584-0) | [19089571](https://pubmed.ncbi.nlm.nih.gov/19089571) | The study reports quantitative PK parameters (half-life, compartmental model) for triamcinolone acetonide in rats, but specific clearance/volume values are not explicitly listed in the provided text. |
| `Rohatagi_1995.pdf` | Rohatagi S et al., Pharmacokinetic and pharmacodynamic eva…, Journal of clinical pharmac… (1995) | popPK | 9 | [10.1002/j.1552-4604.1995.tb04045.x](https://doi.org/10.1002/j.1552-4604.1995.tb04045.x) | [8750370](https://pubmed.ncbi.nlm.nih.gov/8750370) | The study is a clinical PK/PD evaluation of triamcinolone acetonide, but the provided evidence only contains pharmacodynamic parameters (E50, free fraction) and lacks specific quantitative PK values (CL, V, t1/2) which are likely in the full text or figures not included. |
| `Yao_2020.pdf` | Yao Q et al., Development and validation of a LC-MS/M…, Journal of pharmaceutical a… (2020) | popPK | 8 | [10.1016/j.jpba.2019.112980](https://doi.org/10.1016/j.jpba.2019.112980) | [31744668](https://pubmed.ncbi.nlm.nih.gov/31744668) | The study reports a pharmacokinetic model for triamcinolone acetonide in mice, but the specific numeric parameter values are not present in the provided evidence. |
| `Audren_2004.pdf` | Audren F et al., Pharmacokinetic-pharmacodynamic modelin…, Investigative ophthalmology… (2004) | pd | 5 | [10.1167/iovs.03-1110](https://doi.org/10.1167/iovs.03-1110) | [15452046](https://www.ncbi.nlm.nih.gov/pubmed/15452046) | metadata signals extractable PD data (pharmacodynamicmodel) |
| `Daley-Yates_2004.pdf` | Daley-Yates PT et al., Relationship between systemic corticost…, Clinical therapeutics (2004) | pd | 5 | [10.1016/j.clinthera.2004.11.017](https://doi.org/10.1016/j.clinthera.2004.11.017) | [15639702](https://www.ncbi.nlm.nih.gov/pubmed/15639702) | metadata signals extractable PD data (pharmacodynamicmodel) |
| `Derendorf_1993.pdf` | Derendorf H et al., Receptor-based pharmacokinetic-pharmaco…, Journal of clinical pharmac… (1993) | pd | 5 | [10.1002/j.1552-4604.1993.tb03930.x](https://doi.org/10.1002/j.1552-4604.1993.tb03930.x) | [8440759](https://www.ncbi.nlm.nih.gov/pubmed/8440759) | metadata signals extractable PD data (pharmacodynamicmodel) |
| `Meibohm_1999.pdf` | Meibohm B et al., A pharmacokinetic/pharmacodynamic appro…, Journal of pharmacokinetics… (1999) | pd | 5 | [10.1023/a:1020670421957](https://doi.org/10.1023/a:1020670421957) | [10567952](https://www.ncbi.nlm.nih.gov/pubmed/10567952) | metadata signals extractable PD data (PK/PD) |
| `Nakamura_2023.pdf` | Nakamura R et al., Glucocorticoid Dose Dependency on Gene…, The Laryngoscope (2023) | pd | 4 | [10.1002/lary.30330](https://doi.org/10.1002/lary.30330) | [36779842](https://www.ncbi.nlm.nih.gov/pubmed/36779842) | metadata signals extractable PD data (EC50) |
| `Moore_2013.pdf` | Moore CD et al., Metabolic pathways of inhaled glucocort…, Drug metabolism and disposi… (2013) | pgx | 7 | [10.1124/dmd.112.046318](https://doi.org/10.1124/dmd.112.046318) | [23143891](https://www.ncbi.nlm.nih.gov/pubmed/23143891) | metadata signals extractable PGX data (CYP3A, PK/PD-context) |

<sub>queue written 2026-10-04T04:28:18.664190+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Audren_2004 | irrelevant | 0 | 0 | no_text gate: only 150 chars of text extracted (&lt; 400) |
| popPK | Boorman_2023 | irrelevant | 0 | 0 | The study is an in vitro mechanistic investigation of tissue response to triamcinolone, not a pharmacokinetic study reporting disposition parameters. |
| PGx | Camarini_2022 | not_relevant | 0 | 0 | The paper is a systematic review of clinical outcomes for treating bone lesions and does not report any pharmacogenomic effects on PK or PD parameters. |
| popPK | Daley-Yates_2004 | irrelevant | 0 | 0 | no_text gate: only 144 chars of text extracted (&lt; 400) |
| popPK | Derendorf_1993 | irrelevant | 0 | 0 | no_text gate: only 74 chars of text extracted (&lt; 400) |
| PD | Derendorf_1993 | not_relevant | 0 | 0 | The provided text is only the title of a paper and does not contain the full text, data, or numeric PD parameters required to assess the relationship. |
| popPK | Gaffin_2023 | irrelevant | 0 | 0 | The study uses triamcinolone acetonide as a diagnostic probe to assess steroid responsiveness (change in FEV1), not to measure pharmacokinetic parameters like clearance or volume. |
| PGx | García-Martín_2013 | not_relevant | 2 | 1 | The paper is a general review of drug metabolism in allergic diseases and mentions triamcinolone only in the context of metabolic inhibition, without reporting specific pharmacogenomic effects on its PK/PD parameters. |
| PGx | Gerzenstein_2008 | not_relevant | 2 | 0 | The study reports no statistically significant association between glucocorticoid receptor polymorphisms and intraocular pressure response to triamcinolone. |
| PGx | Hagan_2010 | not_relevant | 0 | 0 | The paper reports a drug-drug interaction (nefazodone inhibiting CYP3A4), not a pharmacogenomic effect based on a specific gene variant or genotype. |
| popPK | Katsu_2022 | irrelevant | 0 | 0 | The study is an in-vitro receptor binding/transactivation assay measuring EC50 values for steroid activation of lungfish MR, not a pharmacokinetic study of triamcinolone disposition. |
| popPK | Kelly_1998 | irrelevant | 1 | 0 | The paper is a review discussing general pharmacokinetic principles and relative potency rankings of inhaled corticosteroids without reporting specific quantitative PK parameters (CL, V, etc.) for triamcinolone. |
| PD | Kelly_1998 | not_relevant | 2 | 0 | The text is a qualitative review discussing relative potencies and general dose-response characteristics of inhaled corticosteroids without providing specific numeric PD parameters or extractable concentration-effect curves for triamcinolone. |
| PGx | Leucker_2013 | not_relevant | 0 | 0 | The paper describes a drug-drug interaction (fluoxetine inhibiting CYP3A4) rather than a pharmacogenomic effect based on a specific gene variant or genotype. |
| popPK | Mager_2002 | irrelevant | 2 | 0 | The study focuses on QSAR modeling for a class of corticosteroids and does not report specific quantitative PK parameter values (CL, V, etc.) for triamcinolone in the provided evidence. |
| PD | Mager_2002 | not_relevant | 4 | 2 | The paper focuses on QSAR/QSPKR modeling and mentions predicting the time course of triamcinolone effects, but the provided text does not contain specific numeric PD parameters (Emax, EC50) or explicit concentration-effect data points for triamcinolone. |
| PGx | Mathias_2020 | not_relevant | 0 | 0 | The paper reports a drug-drug interaction (cobicistat inhibiting CYP3A4) rather than a pharmacogenomic effect based on a specific gene variant or genotype. |
| popPK | Meibohm_1999 | irrelevant | 0 | 0 | no_text gate: only 116 chars of text extracted (&lt; 400) |
| PD | Meibohm_1999 | not_relevant | 0 | 0 | The provided text is only the title of a paper and does not contain the full text, data, or numeric PD parameters required to assess the relationship. |
| PGx | Mohan_2021 | not_relevant | 0 | 0 | The paper reports a drug-drug interaction (CYP3A4 inhibition by ritonavir) causing iatrogenic Cushing syndrome, not a pharmacogenomic effect based on a specific gene variant or genotype. |
| PGx | Moore_2013 | not_relevant | 2 | 5 | The paper studies metabolism by different CYP3A isoforms (CYP3A4/5/7) rather than specific genetic variants/polymorphisms, and does not report pharmacogenomic effects on PK/PD parameters. |
| popPK | Nakamura_2023 | irrelevant | 0 | 0 | no_text gate: only 91 chars of text extracted (&lt; 400) |
| PD | Nakamura_2023 | not_relevant | 0 | 0 | The paper investigates gene expression in cell lines (fibroblasts and macrophages) and does not report pharmacokinetic or pharmacodynamic modeling for triamcinolone in a biological system with extractable PD parameters. |
| PGx | Nowak-Sliwinska_2013 | not_relevant | 0 | 0 | The paper reviews photodynamic therapy for polypoidal choroidal vasculopathy and does not discuss triamcinolone pharmacogenomics or PK/PD parameters. |
| PGx | PMID33387367_2021 | not_relevant | 0 | 0 | The paper focuses on opioids (codeine, tramadol, etc.) and does not mention triamcinolone. |
| PGx | Pavek_2005 | not_relevant | 0 | 0 | The paper studies in vitro transporter interactions (BCRP inhibition) and does not report pharmacogenomic effects of gene variants on triamcinolone PK/PD parameters. |
| popPK | Ponsar_2023 | irrelevant | 0 | 0 | The study focuses on in vitro drug release kinetics from 3D-printed implants and does not report in vivo pharmacokinetic parameters (CL, V, ka) for triamcinolone. |
| popPK | Rohatagi_1995 | relevant | 9 | 2 | The study is a clinical PK/PD evaluation of triamcinolone acetonide, but the provided evidence only contains pharmacodynamic parameters (E50, free fraction) and lacks specific quantitative PK values (CL, V, t1/2) which are likely in the full text or figures not included. |
| PGx | Rössner_2018 | not_relevant | 0 | 0 | The paper describes a drug-drug interaction (ritonavir inhibiting CYP3A4) causing adrenal insufficiency, not a pharmacogenomic effect of a gene variant on triamcinolone PK/PD. |
| PGx | Wassner_2017 | not_relevant | 0 | 0 | The paper reports a drug-drug interaction (cobicistat inhibiting CYP3A4) causing adrenal insufficiency, not a pharmacogenomic effect based on a gene variant. |
| popPK | Weber_2013 | irrelevant | 2 | 0 | The paper describes a simulation tool and model structure for inhaled corticosteroids, but the provided evidence contains no specific quantitative PK parameter values (CL, V, etc.) for triamcinolone. |
| PGx | Wurtz_1985 | not_relevant | 0 | 0 | The paper investigates the mechanism of glucocorticoid action (chromatin changes and RNA induction) in cell lines but does not report any pharmacogenomic effects (gene variants) on PK or PD parameters. |
| popPK | Yao_2020 | relevant | 8 | 0 | The study reports a pharmacokinetic model for triamcinolone acetonide in mice, but the specific numeric parameter values are not present in the provided evidence. |
| popPK | Zhang_2008 | irrelevant | 0 | 0 | The study is an in-vitro cell screening model for glucocorticoid receptor activation and does not report pharmacokinetic parameters for triamcinolone. |
| PD | Zhang_2008 | not_relevant | 3 | 2 | The paper reports EC50/IC50 values for dexamethasone and PMA in a cell screening model, but only qualitatively states that triamcinolone acetonide activated the response without providing specific numeric PD parameters or concentration-effect data for triamcinolone. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-10-04 04:28 UTC</sub>
